Expert Interview
A Second Evaluation of Xenon Pharmaceuticals’ Azetukalner (XEN1101) for Focal Onset Seizures ahead of its P3 Data Readout
Ticker(s): XENEInstitution: Johns Hopkins
- Professor of Neurology, Director, Child Neurology Residency Program and Medical Director of the Pediatric Ketogenic Diet Center at Johns Hopkins.
- Treats two patients with CDKL5 deficiency disorder and is familiar with ganaxalone.
- Research focuses on the diagnosis and treatment of childhood seizures and epilepsy, particularly treatments other than medications such as diet, neurostimulation and surgery; one of the world experts on dietary treatment for epilepsy.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
